

उ०प्र० आयुर्विज्ञान विश्वविद्यालय

सैफई, इटावा (उ०प्र०) — 206 130 Uttar Pradesh University of Medical Sciences Saifal, Etawah (U.P.)- 206 130

No. /IEC (990-CD)/UPUMS/2024-25

Date: 02/01/2025

Circular

All faculty members are hereby informed that the university has procured 06 new Multi-Centric Clinical Trial Based Research Projects for the benefit of the faculty researchers of the University.

Any faculty member who is willing to act as PI (Principal Investigator) or Co-PI (Co-Principal Investigator) for any one of the Project (List Of The Projects On Offer Enclosed) is required to submit his application along with his/her credentials at the earliest by 05.02.2025 (Wednesday) of the undersigned.

Final allocation of the projects shall be done by the undersigned.

(Prof. (Dr.) P.K. Jain)

Vice Chancellor

Copy to:-

- 1. All Deans.
- 2. All HOD's.
- 3. Member Secretary(IRC)
- 4. Member Secretary(IEC)
- 5. PPS to Vice Chancellor.
- 6. PA to Pro Vice Chancellor for the information of the Pro Vice Chancellor.
- 7. PA to FO for the information of the Finance Officer.
- 8. PA to Registrar for the information of the Registrar.
- I/C CAC for uploading the circular on the university website at the IEC Circular Tab and Latest Update Tab.

10. Notice Board.

(Prof. (Dr.) P.K. Jain)

Vice Chancellor oh



उ०प्र0 आयुर्विज्ञान विश्वविद्यालय सैफई, इटावा (उ०प्र०) – 206 130

Uttar Pradesh University of Medical Sciences Salfai, Etawah (U.P.)-206 130

06 New Proposed Clinical Trial Projects

	Clinical Trial	Department
Sl No.	Name of the Clinical Trial	General
1	Name of the Clinical Trial A multicenter, randomized, double-blind, active-control phase III clinical trial of WOXheal® [Diperoxochloric acid] topical solution in the treatment of pressure ulcers — in comparison with the active-control 0.9% sodium chloride topical solution in addition to standard of care	Surgery
2	An open label, single-dose, multi-center, randomized, balanced, two-treatment, two-sequence four-period, fully-replicated, pharmacokinetic bioequivalence study of American Regent, Inc. test period, fully-replicated, pharmacokinetic bioequivalence study of American Regent, Inc. test period, fully-replicated, pharmacokinetic bioequivalence study of American Regent, Inc. test period (1.5 mg 1-month) or 4-weeks) and Lupron formulation of Leuprolide acetate for depot suspension) 7.5 mg for 1-month (4-weeks) of AbbVie Inc. North Chicago, IL 60064 administered as an intramuscular injection in adult male prostatic carcinoma patients undergoing initial therapy or receiving a stable regimen of leuprolide acetate for depot suspension via intramuscular injection route	Urology
3	Multicentre prospective & retrospective remnant Biospecimen collection program for study and future biomedical research	Genecology
4	A Randomized, Double-Blind, Multicenter, Two-Period, Two-Treatment, Two-Sequence, Crossover, Multiple-Dose, Steady State Bioequivalence Study of Olaparib Tablets 150 mg (2*150 mg tablets) of Zydus Lifesciences Limited with PrLYNPARZA® Olaparib Tablets 150 mg (2*150 mg tablets) of AstraZeneca Canada Inc., in Adult Patients with Cancer and Stable on Olaparib Therapy under Fasting Condition.	Oncology
5	A phase III, multicenter, randomized, double-blind, parallel-group clinical trial to compare the efficacy and safety of the Cenobamate tablets as adjunctive therapy versus Eslicarbazepine in focal seizures	Neurology
6	A Prospective, multi centre, single arm pivotal study (TAVI), The device consists of Transfermoral delivery catheter and loading system and Transcatheter pericardial aortic valve in size 23, 26 and 29 mm	Cardiology

